PI
Platinum Investment Management Ltd
13F filer · CIK 0001256071Reported Aug 13, 2026
Net seller this quarter
13F portfolio value$407MU.S. long equity reported on 13F
Positions8510 new · 14 closed
Net flow last quarter-$34MBuys minus sells
Top 10 positions weight38.9%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 13, 202685 positions | |||||
| $44.6M | 10.97% | 0.25% | Not reported | Q4 2017 | |
| $20.5M | 5.05% | 0.00% | -24.8% | Q2 2013 | |
| $20.1M | 4.95% | 0.00% | Not reported | Q2 2017 | |
| $14M | 3.45% | 0.05% | -7.3% | Q4 2019 | |
| $12.5M | 3.08% | Not reported | Not reported | Q1 2022 | |
| $9.93M | 2.44% | 0.30% | Not reported | Q1 2019 | |
| $9.89M | 2.43% | 0.00% | Not reported | Q4 2023 | |
| $9.04M | 2.22% | 0.11% | -23.6% | Q3 2024 | |
| $9M | 2.21% | Not reported | Not reported | Q1 2026 | |
| $8.69M | 2.14% | Not reported | Not reported | Q4 2015 | |
| $8.14M | 2.00% | 0.00% | Not reported | Q2 2013 | |
| ATAPGEApogee Therapeutics, Inc. | $7.74M | 1.90% | 0.08% | Not reported | Q3 2023 |
| $7.57M | 1.86% | 0.00% | Not reported | Q1 2025 | |
| $7.07M | 1.74% | 0.00% | Not reported | Q2 2013 | |
| $6.37M | 1.57% | 0.01% | Not reported | Q2 2025 | |
| $5.98M | 1.47% | 0.00% | Not reported | Q1 2019 | |
| $5.97M | 1.47% | 0.09% | +37.6% | Q4 2020 | |
| $5.83M | 1.43% | 0.00% | Not reported | Q1 2025 | |
| $5.64M | 1.39% | 0.00% | Not reported | Q2 2023 | |
| $5.57M | 1.37% | 0.07% | -20.4% | Q3 2021 | |
| $5.28M | 1.30% | 0.05% | Not reported | Q1 2023 | |
| $5.17M | 1.27% | 0.14% | +51.4% | Q3 2020 | |
| $5.16M | 1.27% | 0.02% | Not reported | Q2 2025 | |
| $4.92M | 1.21% | 0.00% | Not reported | Q4 2018 | |
| $4.88M | 1.20% | 0.16% | Not reported | Q2 2023 | |
| $4.85M | 1.19% | 0.04% | +35.1% | Q1 2023 | |
| $4.8M | 1.18% | 0.00% | -6.7% | Q4 2023 | |
| $4.79M | 1.18% | 0.00% | -47.1% | Q4 2025 | |
| $4.79M | 1.18% | Not reported | Not reported | Q2 2025 | |
| $4.74M | 1.16% | 0.03% | -6.7% | Q3 2024 | |
| $4.51M | 1.11% | 0.01% | +33.9% | Q3 2025 | |
| $4.4M | 1.08% | 0.00% | Not reported | Q2 2025 | |
| $4.31M | 1.06% | 0.01% | Not reported | Q3 2022 | |
| $4.19M | 1.03% | 0.00% | Not reported | Q4 2023 | |
| $4.14M | 1.02% | 0.11% | Not reported | Q1 2018 | |
| $3.81M | 0.94% | 0.00% | Not reported | Q2 2023 | |
| $3.71M | 0.91% | 0.06% | -7.4% | Q3 2025 | |
| $3.66M | 0.90% | Not reported | +30.0% | Q2 2015 | |
| $3.62M | 0.89% | 1.00% | +40.6% | Q4 2025 | |
| $3.59M | 0.88% | 0.03% | -4.8% | Q3 2025 | |
| $3.58M | 0.88% | 0.01% | -11.8% | Q3 2025 | |
| $3.58M | 0.88% | 0.00% | Not reported | Q4 2025 | |
| $3.53M | 0.87% | 0.00% | -13.0% | Q3 2025 | |
| $3.34M | 0.82% | 0.07% | Not reported | Q1 2023 | |
| $3.33M | 0.82% | 0.08% | -37.9% | Q4 2024 | |
| $3.3M | 0.81% | 0.04% | -6.7% | Q4 2025 | |
| $3.29M | 0.81% | 0.05% | Not reported | Q1 2026 | |
| $3.27M | 0.80% | 0.01% | Not reported | Q4 2021 | |
| $3.22M | 0.79% | 0.02% | Not reported | Q1 2023 | |
| $3.18M | 0.78% | 0.01% | -18.4% | Q3 2025 | |
| Q1 2026Reported May 14, 202689 positions | |||||
| $50.2M | 12.65% | 0.25% | Not reported | Q4 2017 | |
| $18.9M | 4.77% | 0.06% | -14.4% | Q4 2019 | |
| $16.7M | 4.20% | Not reported | +0.4% | Q1 2022 | |
| $9.92M | 2.50% | 0.00% | -16.8% | Q2 2017 | |
| $9.85M | 2.48% | 0.15% | +11.1% | Q3 2024 | |
| $9.84M | 2.48% | 0.30% | -6.2% | Q1 2019 | |
| $9.32M | 2.35% | Not reported | New | Q1 2026 | |
| $8.1M | 2.04% | 0.00% | -15.2% | Q4 2023 | |
| $8.02M | 2.02% | 0.00% | Not reported | Q1 2019 | |
| $7.99M | 2.01% | 0.00% | -5.1% | Q2 2013 | |
| $7.62M | 1.92% | 0.00% | Not reported | Q2 2013 | |
| $7.05M | 1.78% | Not reported | -33.3% | Q4 2015 | |
| $6.8M | 1.71% | 0.00% | Not reported | Q2 2013 | |
| $6.55M | 1.65% | 0.00% | Not reported | Q1 2025 | |
| $6.2M | 1.56% | 0.01% | Not reported | Q2 2025 | |
| $6.02M | 1.52% | 0.00% | +54.6% | Q4 2025 | |
| $5.93M | 1.50% | 0.00% | Not reported | Q4 2018 | |
| TPTERNTerns Pharmaceuticals, Inc. | $5.84M | 1.47% | 0.10% | Not reported | Q3 2025 |
| $5.64M | 1.42% | Not reported | Not reported | Q2 2025 | |
| CPCNTACentessa Pharmaceuticals PLC | $5.47M | 1.38% | 0.09% | -11.2% | Q2 2023 |
| $4.96M | 1.25% | 0.01% | Not reported | Q1 2024 | |
| $4.94M | 1.24% | 0.03% | -6.3% | Q3 2024 | |
| $4.92M | 1.24% | 0.00% | Not reported | Q2 2023 | |
| ATAPGEApogee Therapeutics, Inc. | $4.91M | 1.24% | 0.08% | -15.8% | Q3 2023 |
| $4.81M | 1.21% | 0.00% | Not reported | Q3 2022 | |
| $4.6M | 1.16% | 0.01% | Not reported | Q3 2022 | |
| $4.57M | 1.15% | 0.18% | -4.8% | Q2 2023 | |
| $4.55M | 1.15% | 0.02% | Not reported | Q2 2025 | |
| $4.53M | 1.14% | 0.00% | +2.0% | Q4 2023 | |
| $4.52M | 1.14% | 0.09% | Not reported | Q3 2021 | |
| $4.51M | 1.14% | 0.00% | +34.1% | Q2 2023 | |
| $4.51M | 1.14% | 0.07% | Not reported | Q1 2023 | |
| $4.5M | 1.13% | 0.00% | Not reported | Q1 2025 | |
| $4.4M | 1.11% | 0.01% | -8.9% | Q3 2025 | |
| $4.39M | 1.11% | 0.12% | +72.6% | Q4 2024 | |
| $4.31M | 1.09% | 0.07% | -7.6% | Q4 2020 | |
| $4.06M | 1.02% | 0.05% | -27.6% | Q1 2023 | |
| $3.78M | 0.95% | 0.00% | -13.5% | Q3 2025 | |
| $3.76M | 0.95% | 0.00% | -24.9% | Q1 2021 | |
| $3.72M | 0.94% | 0.78% | Not reported | Q2 2024 | |
| $3.66M | 0.92% | 0.03% | +3.2% | Q1 2025 | |
| $3.64M | 0.92% | 0.04% | +20.0% | Q4 2025 | |
| $3.63M | 0.91% | 0.01% | -11.9% | Q3 2025 | |
| $3.45M | 0.87% | 0.00% | -25.0% | Q4 2015 | |
| $3.43M | 0.86% | 0.06% | -2.0% | Q3 2025 | |
| $3.22M | 0.81% | 0.03% | -23.9% | Q1 2023 | |
| $3.13M | 0.79% | 0.02% | +19.2% | Q1 2024 | |
| $3.09M | 0.78% | 0.02% | Not reported | Q1 2023 | |
| $3.05M | 0.77% | 0.10% | -24.0% | Q3 2020 | |
| $2.9M | 0.73% | 0.11% | Not reported | Q1 2018 | |
| Q4 2025Reported Feb 13, 2026124 positions | |||||
| $41.7M | 9.63% | 0.25% | -11.2% | Q4 2017 | |
| $31.9M | 7.37% | 0.07% | -6.4% | Q4 2019 | |
| $16.1M | 3.72% | Not reported | -3.3% | Q1 2022 | |
| $11.6M | 2.67% | Not reported | -71.5% | Q4 2015 | |
| $10.7M | 2.47% | 0.00% | -85.5% | Q4 2023 | |
| $10.6M | 2.46% | 0.32% | -17.9% | Q1 2019 | |
| $10.1M | 2.34% | 0.13% | -4.8% | Q3 2024 | |
| $9.56M | 2.21% | 0.00% | -90.3% | Q2 2017 | |
| $8.89M | 2.06% | 0.00% | -11.4% | Q1 2019 | |
| $7.17M | 1.66% | 0.00% | -26.7% | Q2 2023 | |
| $7.11M | 1.64% | 0.00% | -94.7% | Q2 2013 | |
| $6.88M | 1.59% | 0.00% | -91.9% | Q1 2025 | |
| $6.66M | 1.54% | 0.00% | -93.3% | Q2 2013 | |
| $6.52M | 1.51% | 0.02% | -25.2% | Q3 2025 | |
| $6.11M | 1.41% | 0.04% | -28.4% | Q1 2023 | |
| $6.05M | 1.40% | 0.19% | -25.3% | Q2 2023 | |
| $6.03M | 1.39% | 0.01% | -90.8% | Q2 2025 | |
| $6.02M | 1.39% | 0.02% | -92.7% | Q2 2025 | |
| $5.98M | 1.38% | 0.03% | -11.1% | Q3 2024 | |
| $5.94M | 1.37% | 0.07% | -19.4% | Q1 2023 | |
| $5.76M | 1.33% | 0.00% | -93.5% | Q2 2013 | |
| $5.56M | 1.29% | Not reported | -91.4% | Q2 2025 | |
| $5.55M | 1.28% | 0.00% | -35.6% | Q4 2018 | |
| $5.48M | 1.27% | 0.00% | -91.9% | Q1 2025 | |
| $5.28M | 1.22% | 0.01% | +5.0% | Q1 2024 | |
| $5.26M | 1.22% | 0.00% | Not reported | Q2 2023 | |
| ATAPGEApogee Therapeutics, Inc. | $5.22M | 1.21% | 0.10% | -26.2% | Q3 2023 |
| $5.17M | 1.19% | 0.00% | -12.6% | Q4 2024 | |
| $5.16M | 1.19% | 0.01% | -94.7% | Q1 2021 | |
| $5.16M | 1.19% | 0.00% | -39.5% | Q4 2023 | |
| $5.01M | 1.16% | 0.00% | -95.8% | Q4 2015 | |
| $4.85M | 1.12% | 0.00% | -92.8% | Q2 2023 | |
| $4.62M | 1.07% | 0.09% | -7.1% | Q3 2021 | |
| $4.62M | 1.07% | Not reported | -6.7% | Q2 2015 | |
| $4.58M | 1.06% | 0.00% | -5.0% | Q3 2025 | |
| TPTERNTerns Pharmaceuticals, Inc. | $4.47M | 1.03% | 0.10% | -11.5% | Q3 2025 |
| $4.37M | 1.01% | 0.02% | +18.2% | Q1 2024 | |
| $4.31M | 1.00% | 0.08% | -44.8% | Q4 2020 | |
| $4.2M | 0.97% | 0.06% | +14.8% | Q3 2025 | |
| $4.17M | 0.96% | 0.14% | -27.8% | Q3 2020 | |
| $4.17M | 0.96% | 0.01% | -84.3% | Q3 2025 | |
| $4.15M | 0.96% | 0.00% | Not reported | Q2 2013 | |
| $4.1M | 0.95% | 0.03% | -21.0% | Q4 2021 | |
| $3.92M | 0.91% | 0.12% | -13.9% | Q1 2018 | |
| CPCNTACentessa Pharmaceuticals PLC | $3.88M | 0.90% | 0.10% | -16.8% | Q2 2023 |
| $3.88M | 0.90% | 0.01% | -93.7% | Q3 2022 | |
| $3.82M | 0.88% | 0.02% | -92.7% | Q1 2023 | |
| $3.65M | 0.84% | 0.02% | -23.3% | Q1 2025 | |
| $3.63M | 0.84% | 0.24% | Not reported | Q3 2025 | |
| $3.5M | 0.81% | 0.79% | -14.4% | Q2 2024 | |
| Q3 2025Reported Nov 13, 2025120 positions | |||||
| $100M | 6.49% | 0.10% | +71.6% | Q1 2021 | |
| $92.7M | 5.99% | 0.00% | -38.2% | Q4 2015 | |
| $85.7M | 5.54% | 0.02% | +1.3% | Q1 2025 | |
| $79.2M | 5.12% | 0.02% | -2.9% | Q2 2013 | |
| $78.8M | 5.09% | 0.04% | +7.2% | Q2 2013 | |
| $78.7M | 5.09% | 0.04% | -16.1% | Q2 2013 | |
| $77M | 4.98% | 0.05% | -21.5% | Q2 2017 | |
| $70.3M | 4.54% | 0.00% | -24.8% | Q4 2023 | |
| $69.8M | 4.51% | 0.22% | -5.9% | Q2 2025 | |
| $67.4M | 4.36% | 0.05% | +5.7% | Q2 2023 | |
| $66M | 4.27% | 0.16% | Not reported | Q2 2025 | |
| $59M | 3.81% | 0.04% | -48.1% | Q1 2025 | |
| $58.7M | 3.79% | Not reported | -35.1% | Q2 2025 | |
| $56.6M | 3.66% | 0.15% | -32.7% | Q3 2022 | |
| $51.5M | 3.33% | 0.32% | -13.9% | Q1 2023 | |
| $47M | 3.04% | 1.38% | -16.1% | Q1 2023 | |
| $43.1M | 2.79% | 0.28% | -11.2% | Q4 2017 | |
| $35.7M | 2.30% | 0.07% | -10.0% | Q4 2019 | |
| $31.4M | 2.03% | Not reported | -31.3% | Q4 2015 | |
| $28.7M | 1.85% | 0.06% | New | Q3 2025 | |
| $15M | 0.97% | 0.39% | -7.4% | Q1 2019 | |
| $13.8M | 0.89% | Not reported | Not reported | Q1 2022 | |
| $11.8M | 0.76% | 0.14% | +116.7% | Q3 2024 | |
| $11.7M | 0.76% | 0.00% | Not reported | Q1 2019 | |
| $9.31M | 0.60% | 0.00% | -13.9% | Q2 2023 | |
| $8.3M | 0.54% | 0.00% | -3.6% | Q4 2023 | |
| $7.72M | 0.50% | 0.02% | New | Q3 2025 | |
| $7.16M | 0.46% | 0.01% | Not reported | Q4 2018 | |
| $7.08M | 0.46% | 0.00% | -30.0% | Q4 2024 | |
| $6.26M | 0.40% | 0.03% | -5.3% | Q3 2024 | |
| $5.92M | 0.38% | 0.01% | -42.5% | Q2 2024 | |
| $5.85M | 0.38% | 0.01% | Not reported | Q1 2024 | |
| $5.67M | 0.37% | 0.00% | New | Q3 2025 | |
| $5.51M | 0.36% | Not reported | -50.9% | Q2 2015 | |
| $5.49M | 0.35% | 0.25% | New | Q3 2025 | |
| $5.26M | 0.34% | 0.00% | -4.1% | Q2 2023 | |
| $4.64M | 0.30% | 0.25% | Not reported | Q2 2023 | |
| $4.64M | 0.30% | 0.01% | -15.4% | Q1 2024 | |
| $4.63M | 0.30% | 1.03% | -16.6% | Q2 2024 | |
| $4.54M | 0.29% | 0.19% | Not reported | Q3 2020 | |
| CPCNTACentessa Pharmaceuticals PLC | $4.52M | 0.29% | 0.14% | -35.9% | Q2 2023 |
| $4.44M | 0.29% | 0.00% | -8.2% | Q2 2013 | |
| $4.42M | 0.29% | 0.06% | New | Q3 2025 | |
| $3.97M | 0.26% | 0.05% | -25.0% | Q4 2024 | |
| $3.83M | 0.25% | 0.08% | Not reported | Q1 2023 | |
| ATAPGEApogee Therapeutics, Inc. | $3.72M | 0.24% | 0.16% | +8.3% | Q3 2023 |
| $3.62M | 0.23% | 0.03% | -50.3% | Q4 2021 | |
| $3.44M | 0.22% | 0.07% | +63.9% | Q1 2023 | |
| $3.31M | 0.21% | 0.01% | -12.2% | Q1 2023 | |
| $3.23M | 0.21% | 0.03% | -17.8% | Q1 2025 | |
Premium opens every quarter this fund has filed